admin

purixlab

Retatrutide: What the Phase 1–3 Clinical Trial Series Shows, and What Is Still Unknown

A research overview of retatrutide, the investigational GIP/GLP-1/glucagon triple-receptor agonist: phase 1 and 1b data, phase 2 obesity, diabetes and liver-fat studies, the first published phase 3 results (TRIUMPH-1, TRIUMPH-2, TRANSCEND-T2D-1), open questions, and product-quality findings. PurixLab’s Retatrutide 10mg vial is for laboratory research use only.

Retatrutide: What the Phase 1–3 Clinical Trial Series Shows, and What Is Still Unknown Read More »

GLOW BLEND 70mg: What the Research Says About BPC-157, TB-500 and GHK-Cu

What published research reports on the three components of GLOW BLEND 70mg (BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg): preclinical findings for each, the difference between TB-500 and thymosin β4, the limited data on combinations, open questions, and PurixLab details (laboratory research use only).

GLOW BLEND 70mg: What the Research Says About BPC-157, TB-500 and GHK-Cu Read More »

What is MOTS-c? A Research Overview of the Mitochondrial-Derived Peptide

An evidence-based overview of MOTS-c, the 16-amino-acid peptide encoded in mitochondrial DNA: discovery, AMPK and nuclear-signalling findings in cells and mice, human observational and genetic studies, open questions, general lab storage, and PurixLab’s MOTS-C 10mg research vial (laboratory research use only).

What is MOTS-c? A Research Overview of the Mitochondrial-Derived Peptide Read More »